Molecular Residual Disease detection in early stage breast cancer with a personalized sequencing approach Read more about Molecular Residual Disease detection in early stage breast cancer with a personalized sequencing approach
Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer Read more about Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer
Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma Read more about Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma
A personalised sequencing approach for liquid biopsy-based detection of recurrent disease in early-stage breast cancer Read more about A personalised sequencing approach for liquid biopsy-based detection of recurrent disease in early-stage breast cancer
Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study Read more about Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study
Detection of early-stage breast cancer recurrence using a personalised liquid biopsy-based sequencing approach Read more about Detection of early-stage breast cancer recurrence using a personalised liquid biopsy-based sequencing approach
Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay Read more about Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay
Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC) Read more about Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC)
Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC Read more about Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC
Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma Read more about Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma